| __timestamp | BioMarin Pharmaceutical Inc. | Veracyte, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 302156000 | 40786000 |
| Thursday, January 1, 2015 | 402271000 | 47876000 |
| Friday, January 1, 2016 | 476593000 | 52035000 |
| Sunday, January 1, 2017 | 554336000 | 55348000 |
| Monday, January 1, 2018 | 604353000 | 65276000 |
| Tuesday, January 1, 2019 | 680924000 | 82720000 |
| Wednesday, January 1, 2020 | 737669000 | 89118000 |
| Friday, January 1, 2021 | 759375000 | 181193000 |
| Saturday, January 1, 2022 | 854009000 | 174078000 |
| Sunday, January 1, 2023 | 937300000 | 184232000 |
| Monday, January 1, 2024 | 1009025000 |
Unveiling the hidden dimensions of data
In the competitive world of biotechnology, managing operational costs is crucial for success. BioMarin Pharmaceutical Inc. and Veracyte, Inc. offer a fascinating study in contrasts when it comes to Selling, General, and Administrative (SG&A) expenses. Over the past decade, BioMarin has seen its SG&A expenses grow by approximately 210%, from $302 million in 2014 to $937 million in 2023. This reflects a strategic investment in scaling operations and expanding market reach. Meanwhile, Veracyte's SG&A expenses have increased by about 350%, from $41 million to $184 million over the same period, indicating a rapid growth phase. Despite the disparity in absolute numbers, both companies demonstrate a commitment to leveraging SG&A spending to fuel growth. This analysis provides a window into how biotech firms balance cost management with strategic expansion, a critical factor in their long-term success.
SG&A Efficiency Analysis: Comparing Pfizer Inc. and BioMarin Pharmaceutical Inc.
Selling, General, and Administrative Costs: Viatris Inc. vs Veracyte, Inc.
Comparing SG&A Expenses: BioMarin Pharmaceutical Inc. vs Opthea Limited Trends and Insights
BioMarin Pharmaceutical Inc. and Viking Therapeutics, Inc.: SG&A Spending Patterns Compared
SG&A Efficiency Analysis: Comparing BioMarin Pharmaceutical Inc. and ImmunityBio, Inc.
SG&A Efficiency Analysis: Comparing BioMarin Pharmaceutical Inc. and Amphastar Pharmaceuticals, Inc.
Breaking Down SG&A Expenses: Ascendis Pharma A/S vs Veracyte, Inc.
Comparing SG&A Expenses: Madrigal Pharmaceuticals, Inc. vs Veracyte, Inc. Trends and Insights
Comparing SG&A Expenses: Alkermes plc vs Veracyte, Inc. Trends and Insights
Who Optimizes SG&A Costs Better? Veracyte, Inc. or Protagonist Therapeutics, Inc.
Breaking Down SG&A Expenses: Veracyte, Inc. vs Mesoblast Limited
Comparing SG&A Expenses: Veracyte, Inc. vs Xencor, Inc. Trends and Insights